ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for gout.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gout is a prevalent and debilitating form of inflammatory arthritis caused by the deposition of monosodium urate crystals resulting from sustained hyperuricemia. Despite the availability of urate-lowering therapies, a substantial proportion of patients continue to experience recurrent flares or face treatment limitations, underscoring the urgent need for alternative therapeutic strategies. Recent advances in human genetics, particularly the application of genome-wide Mendelian randomization, enable systematic evaluation of druggable targets and provide a powerful approach to accelerate the discovery of novel therapeutic interventions for gout. We performed two-sample Mendelian randomization (MR) integrating druggable genes with cis-eQTL data from human blood to evaluate their causal effects on gout. Replication analysis was conducted in an independent gout GWAS cohort, and significant signals were further examined via SMR, HEIDI, and Bayesian colocalization to strengthen causal inference. To investigate potential mechanisms, mediation MR was applied to relevant biomarkers, and phenome-wide MR was employed to assess side effects and pleiotropic effects. Finally, the candidate genes were cross-referenced with pharmacological databases to identify actionable drugs. Using genome-wide druggable Mendelian randomization analysis combined with replication, SMR with HEIDI testing, and Bayesian colocalization, we identified three high-confidence druggable genes with potential causal roles in gout: KAT5, THBS3, and MAP3K11. Two-step MR suggested that KAT5 may influence gout risk indirectly via uric acid levels. Phe-MR indicated minimal potential adverse effects for KAT5, whereas MAP3K11 and THBS3 may be associated with altered risks of certain diseases. Drug target evaluation revealed that MAP3K11 is already addressed by approved therapeutics, suggesting strong repurposing potential, whereas THBS3 and KAT5 may serve as early leads for the development of therapeutics with novel mechanisms in gout. This study provides genetic evidence supporting KAT5, THBS3, and MAP3K11 as priority therapeutic targets in gout, offering valuable guidance for subsequent targeted drug development and repurposing.
Indexed as
Identifiers
41212276What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.